AstraZeneca will present new clinical and real-world data from its expansive respiratory portfolio at the American Thoracic Society (ATS) International Conference, held from May 17 - 22, 2024, in San Diego, California. The company will spotlight 59 abstracts, including 12 late-breaking posters, highlighting advances in treatments for chronic respiratory diseases such as COPD, severe asthma, and eosinophilic granulomatosis with polyangiitis (EGPA).

Dr. Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, emphasized the significance of the presentations, stating, “Our data at ATS underline our strides in pushing the boundaries of science towards disease modification and potential cures. Our Phase IIa COURSE data exploring tezepelumab in a broad COPD patient population is particularly promising and exemplifies our commitment to addressing unmet needs in respiratory care.”

The ATS conference will serve as a platform for AstraZeneca to demonstrate its leadership in respiratory science, particularly through the innovative use of biologics and inhaled therapies. Key highlights include the investigation of TEZSPIRE® (tezepelumab) and tozorakimab for their potential roles in modulating disease pathways beyond traditional treatment scopes.

Ruud Dobber, Ph.D., Executive Vice President and President of the BioPharmaceuticals Business Unit, elaborated on the company’s vision, “Our robust portfolio and pipeline of respiratory therapies showcase our ambition to transform care for COPD patients globally. At ATS, we will also highlight critical real-world evidence supporting the cardiopulmonary benefits of our inhaled triple therapy BREZTRI®.”

Featured studies at ATS 2024 include:

• COURSE Phase IIa: Proof-of-concept data on tezepelumab in moderate to severe COPD patients, expanding potential treatment benefits across a diverse patient group.
• ETHOS Phase III: Post-hoc analysis detailing the impact of BREZTRI® on a spectrum of cardiopulmonary outcomes, aimed at enhancing understanding of COPD’s broader health impacts.
• EXACOS-CV Study: Late-breaking real-world data from over one million COPD patients, assessing the risk of serious cardiovascular events post-exacerbation.

AstraZeneca is also advancing asthma treatment with AIRSUPRA®, a novel anti-inflammatory rescue therapy. The upcoming ACADIA trial and a post-hoc analysis from the MANDALA study will provide further insights into its efficacy across varying patient demographics.

The ATS 2024 presentations underscore AstraZeneca’s dedication to pioneering the next generation of respiratory therapies, with the goal of improving patient outcomes through science-driven innovation.